Korea Basic Science Institute

Yonsei University

Ju Yeon Lee

Jong Shin Yoo

Jin Young Kim

Hye Jung Chang

Eun Soo Park

Do Hyang Kim

Gun Wook Park

Hyun Kyoung Lee

Won Tae Kim

Kwee Hyun Suh

Tae Hee Ha

Maeng Sup Kim

Eun Joo Kwak

Mi Young Cha

Kwang Ok Lee

Ji Young Jeon

Jae-Han Kim

Mi Ra Kim

Hyun Joo An

Joon Seok Kyeong

Byung Joo Park

Kwang Hoe Kim

Men Hua

Jong Hyun Na

The present invention relates to a bioinformation processing analysis method for the identification and quantification of O-linked glycopeptide using high resolution mass spectrum. Particularly, according to the bioinformation processing analysis method of the present invention, the quantitative changes of O-linked glycopeptide containing non-informed sugar chains included in various samples can be efficiently and accurately analyzed; the prediction or diagnosis of disease including cancer can be made easy by using a high resolution mass spectrometer; or the investigation of O-linked glycopeptide structure of a therapeutic glycoprotein can be efficiently achieved.

Bioinformatics platform for high-throughput identification and quantification of O-glycopeptide

The present invention relates to a diagnosis method of liver cancer using mass spectrometry of &#x3b1;-fetoprotein derived glycopeptide. Particularly, according to the AFP glycopeptide analysis method of the invention, fucosylation rate of the glycopeptide having the sequence composed of Val-Asn-Phe-Thr-Glu-Ile-Gln-Lys is analyzed to diagnose liver cancer in the early developmental grade. In particular, fucosylation rate is higher in the liver cancer patients than in other liver disease patients, so that the comparison of the fucosylation rate can be useful to diagnose or distinguish liver cancer from other liver diseases in the early HCC patients.

Diagnostic method of liver cancer using &#x3b1;-fetoprotein derived glycopeptides by mass spectrometry

The present invention relates to a more efficient and accurate method for the identification and quantification of comparatively low abundant glycopeptides, compared with general peptides, using mass spectrum obtained by using high resolution mass spectrometer. Therefore, the method of the present invention can be effectively used for the techniques for identification of biotherapeutics and diagnosis of cancer or disease by screening glycopeptide, the disease marker (Biomarker), from various samples.

Bioinformatics platform for high-throughput identification and quantification of N&#x2014;glycopeptide

Disclosed is a magnesium based amorphous alloy having a good glass forming ability and ductility. The Mg based amorphous alloy has a composition range of MgABwhere x and y are respectively 2.5&#x2266;x&#x2266;30, 2.5&#x2266;y&#x2266;20 in atomic percent. Here, A includes at least one element selected from the group consisting of Cu, Ni, Zn, Al, Ag, and Pd, and B includes at least one element selected from the group consisting of Gd, Y, Ca, and Nd.

Magnesium based amorphous alloy having improved glass forming ability and ductility

Disclosed is a single-phase amorphous alloy having an enhanced ductility. The single-phase amorphous alloy has a composition range of ABCwhere a and b are respectively 0&#x3c;a&#x3c;15, 0&#x2266;b&#x2266;30 in atomic percent. Here, A includes at least one element selected from the group consisting of Be, Mg, Ca, Ti, Zr, Hf, Pt, Pd, Fe, Ni, and Cu. B includes at least one element selected from the group consisting of Y, La, Gd, Nb, Ta, Ag, Au, Co, and Zn. C includes at least one element selected from the group consisting of Al, In, Sn, B, C, Si, and P.

Monolithic metallic glasses with enhanced ductility

Growing community of inventors

Daejeon, South Korea

Ju Yeon Lee